Literature DB >> 11600746

Anti-fibrillarin antibodies in systemic sclerosis.

V J Tormey1, C C Bunn, C P Denton, C M Black.   

Abstract

OBJECTIVES: To investigate the nature and extent of organ involvement in anti-fibrillarin antibody (AFA)-positive patients within a UK systemic sclerosis (SSc) population.
METHODS: We investigated 1026 consecutive patients with SSc. AFA was identified by the characteristic clumpy nucleolar and coilin body pattern of staining in interphase cells and staining of fibrillarin in metaphase cells by indirect immunofluorescence using HEp-2 cells. Identity of the 34-kDa fibrillarin protein was confirmed by immunoprecipitation from [(35)S]methionine-labelled HeLa cell extract.
RESULTS: AFA was detected in 42 patients (4.1%) with early disease onset (mean age 36 yr). Sixteen (38%) patients had limited cutaneous (lcSSc) and 26 (62%) diffuse cutaneous SSc (dcSSc). All eight Afro-Caribbean patients with AFA had dcSSc whereas the Caucasians were equally divided between dcSSc and lcSSc. Within the dcSSc subgroup, 54% had myositis, 35% had pulmonary hypertension, 15% had cardiac involvement and 23% had renal involvement.
CONCLUSIONS: AFA identifies young SSc patients with frequent internal organ involvement, especially pulmonary hypertension, myositis and renal disease. In contrast to previous reports, AFA was not restricted to dcSSc patients in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600746     DOI: 10.1093/rheumatology/40.10.1157

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  28 in total

Review 1.  N-TproBNP as biomarker in systemic sclerosis.

Authors:  Tommaso Schioppo; Carolina Artusi; Teresa Ciavarella; Francesca Ingegnoli; Antonella Murgo; Silvana Zeni; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

3.  Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis.

Authors:  Lisa K Peterson; Troy D Jaskowski; Maureen D Mayes; Anne E Tebo
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

4.  Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis.

Authors:  Carolina Mejia Otero; Shervin Assassi; Marie Hudson; Maureen D Mayes; Rosa Estrada-Y-Martin; Claudia Pedroza; Tingting W Mills; Jennifer Walker; Murray Baron; Wendy Stevens; Susanna M Proudman; Mandana Nikpour; Sonal Mehra; Mianbo Wang; Marvin J Fritzler
Journal:  J Rheumatol       Date:  2017-04-01       Impact factor: 4.666

5.  Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.

Authors:  Hadi Poormoghim; Alireza Salek Moghadam; Maziar Moradi-Lakeh; Mehrzad Jafarzadeh; Behnam Asadifar; Mohsen Ghelman; Elham Andalib
Journal:  Rheumatol Int       Date:  2013-01-24       Impact factor: 2.631

Review 6.  Stressing on the nucleolus in cardiovascular disease.

Authors:  Nirmala Hariharan; Mark A Sussman
Journal:  Biochim Biophys Acta       Date:  2013-10-24

Review 7.  Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Authors:  Ulrich A Walker; Philip J Clements; Yannick Allanore; Oliver Distler; Chester V Oddis; Dinesh Khanna; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 8.  The Clinical Features of Myositis-Associated Autoantibodies: a Review.

Authors:  Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 9.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

10.  Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.

Authors:  Jennifer C Parker; Rufus W Burlingame; Christopher C Bunn
Journal:  J Autoimmune Dis       Date:  2009-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.